Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company reports developments in lens-based refractive surgery through its EVO family of Implantable Collamer® Lenses, including EVO ICL™ for vision correction. The company designs, manufactures and sells implantable lenses for the eye and related delivery systems, with ICL products forming the core of its revenue base.
Recurring updates cover quarterly and annual results, preliminary sales, strategic-plan progress, market trends in China, the Americas and other international markets, regulatory indication changes, clinical evidence for EVO ICL, product adoption milestones, board and executive transitions, and shareholder voting or governance matters.
Alcon (SIX/NYSE: ALC) and STAAR Surgical (NASDAQ: STAA) agreed to adjourn STAAR’s Special Meeting of Stockholders originally scheduled for October 23, 2025 in connection with STAAR’s merger agreement with Alcon. The Special Meeting is adjourned until 8:30 a.m. Pacific Time on November 6, 2025. No other business will be conducted at the Special Meeting. The record date for stockholders eligible to vote remains the close of business on September 12, 2025. Stockholders with voting questions are directed to contact STAAR’s proxy solicitor, Innisfree M&A Incorporated, at toll-free +1 877-750-8233 or banks/brokers +1 212-750-5833.
Summary not available.
Yunqi Capital (NASDAQ:STAA), a 5.1% STAAR shareholder, urged the board to hold the special shareholder meeting on October 23, 2025 and reiterated its opposition to the proposed sale to Alcon. Yunqi criticized STAAR’s pre-merger process and called recent company disclosures “disingenuous.”
Yunqi highlighted preliminary Q3 results: China revenue YTD $142.6M, estimated Q3 China revenue ≈$54.4M, $25.6M consignment revenue, and said Q3 sales exceeded consensus by 2.8%. Yunqi projects China sales of $180–200M for 2026 versus STAAR’s $160M guide and flagged missing margin/profit detail before the vote.
Summary not available.
STAAR Surgical (NASDAQ: STAA) reported preliminary Q3 2025 net sales of $94.7 million, a 6.9% increase versus $88.6 million a year earlier. Results included $25.9 million recognized in Q3 from a December 2024 ICL shipment to a China distributor that received extended payment terms.
Excluding that collection, the company saw 7.7% growth outside China while China distributors reduced purchases, lowering nine-month sales as they trimmed inventory by approximately $80–$85 million. Figures are unaudited and subject to final 10-Q review. A special stockholder meeting on Oct 23, 2025 will vote on the Alcon merger proposal.
Broadwood Partners (NASDAQ: STAA), which holds 27.5% of STAAR outstanding shares, sent a letter to STAAR Surgical’s board on October 17, 2025 urging directors to allow a timely shareholder vote on the proposed sale to Alcon (NYSE: ALC). Broadwood urges shareholders to vote AGAINST the acquisition announced August 5, 2025, arguing the board pursued a poorly designed process and an inadequate price.
Broadwood warns the board against delaying the October 23, 2025 vote or issuing misleading statements, and says shareholders and proxy advisors oppose the deal; it calls for the board to accept the vote result and work with shareholders if the transaction is rejected.
Summary not available.
Summary not available.
Summary not available.
STAAR Surgical (NASDAQ: STAA) reiterated its board's unanimous recommendation that stockholders vote FOR the merger with Alcon on the white proxy card.
Key points: Alcon's offer is $28.00 per share in cash (a 59% premium to the 90-day VWAP). STAAR contrasts this with Broadwood's position and a prior price of $18.49 per share, warning a vote against could invite control shifts and valuation pressure. Stockholders are urged to contact STAAR's proxy solicitor for voting assistance.